Volume 79, Issue 1, Pages (January 2011)

Slides:



Advertisements
Similar presentations
Volume 77, Issue 9, Pages (May 2010)
Advertisements

Volume 67, Issue 4, Pages (April 2005)
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
Volume 78, Issue 11, Pages (December 2010)
Progranulin protects against renal ischemia/reperfusion injury in mice
Volume 76, Issue 7, Pages (October 2009)
Volume 88, Issue 3, Pages (September 2015)
Volume 79, Issue 2, Pages (January 2011)
Li-Wen Lai, Kim-Chong Yong, Yeong-Hau H. Lien  Kidney International 
Volume 84, Issue 3, Pages (September 2013)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule–specific knockout mouse models  Qingqing Wei, Guie Dong,
Volume 79, Issue 9, Pages (May 2011)
Volume 75, Issue 3, Pages (February 2009)
Volume 75, Issue 2, Pages (January 2009)
Volume 63, Issue 4, Pages (April 2003)
Volume 79, Issue 1, Pages (January 2011)
Volume 70, Issue 2, Pages (July 2006)
Volume 73, Issue 4, Pages (February 2008)
Paricalcitol attenuates cyclosporine-induced kidney injury in rats
Volume 82, Issue 9, Pages (November 2012)
Volume 63, Issue 2, Pages (February 2003)
Volume 54, Issue 6, Pages (January 1998)
Autophagy in proximal tubules protects against acute kidney injury
JNK mediates hepatic ischemia reperfusion injury
Volume 81, Issue 4, Pages (February 2012)
Volume 67, Issue 6, Pages (June 2005)
Decreased renal ischemia–reperfusion injury by IL-16 inactivation
Gilbert R. Kinsey, Liping Huang, Amy L. Vergis, Li Li, Mark D. Okusa 
Volume 75, Issue 8, Pages (April 2009)
Volume 80, Issue 12, Pages (December 2011)
Ischemic and non-ischemic acute kidney injury cause hepatic damage
Volume 61, Issue 3, Pages (March 2002)
Volume 68, Issue 4, Pages (October 2005)
Volume 66, Issue 6, Pages (December 2004)
Volume 83, Issue 3, Pages (March 2013)
Kenji Kasuno, Hajime Nakamura, Takahiko Ono, Eri Muso, Junji Yodoi 
Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury  Jianchun Chen, Jian-Kang.
Volume 73, Issue 12, Pages (June 2008)
Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin- induced acute kidney injury  K. Negishi, E. Noiri, R. Maeda, D.
Volume 85, Issue 1, Pages (January 2014)
Volume 56, Issue 3, Pages (September 1999)
Volume 73, Issue 11, Pages (June 2008)
Genetic deficiency of adiponectin protects against acute kidney injury
Volume 67, Issue 4, Pages (April 2005)
Volume 74, Issue 5, Pages (September 2008)
Volume 85, Issue 4, Pages (April 2014)
Volume 85, Issue 4, Pages (April 2014)
The pathological role of Bax in cisplatin nephrotoxicity
20-HETE in acute kidney injury
Volume 75, Issue 5, Pages (March 2009)
Volume 83, Issue 6, Pages (June 2013)
Induction of heat shock protein 70 inhibits ischemic renal injury
Volume 79, Issue 2, Pages (January 2011)
Volume 74, Issue 1, Pages (July 2008)
Volume 88, Issue 4, Pages (October 2015)
Volume 60, Issue 6, Pages (December 2001)
Volume 75, Issue 5, Pages (March 2009)
Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials  Christof Westenfelder, Florian E. Togel 
Volume 63, Issue 1, Pages (January 2003)
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
Volume 80, Issue 2, Pages (July 2011)
Volume 58, Issue 5, Pages (November 2000)
Volume 60, Issue 3, Pages (September 2001)
Volume 65, Issue 3, Pages (March 2004)
A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia–reperfusion injury  L.-W. Lai, K.-C. Yong,
Volume 75, Issue 5, Pages (March 2009)
Volume 85, Issue 1, Pages (January 2014)
Volume 75, Issue 8, Pages (April 2009)
Volume 54, Issue 2, Pages (August 1998)
Presentation transcript:

Volume 79, Issue 1, Pages 57-65 (January 2011) Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury  Uwe Hoff, Ivo Lukitsch, Lyubov Chaykovska, Mechthild Ladwig, Cosima Arnold, Vijay L. Manthati, T. Florian Fuller, Wolfgang Schneider, Maik Gollasch, Dominik N. Muller, Bert Flemming, Erdmann Seeliger, Friedrich C. Luft, John R. Falck, Duska Dragun, Wolf-Hagen Schunck  Kidney International  Volume 79, Issue 1, Pages 57-65 (January 2011) DOI: 10.1038/ki.2010.377 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Ischemia/reperfusion (I/R)-induced release of 20-hydroxyeicosatetraenoic acid (20-HETE). (a) In isolated perfused kidneys, I/R induced an increased release of 20-HETE that was partially blocked by HET0016. Data are given as mean±s.e.m. (n=6 per group). #P<0.05 vs basal 20-HETE release 5min before ischemia; *P<0.05 for vehicle vs HET0016. (b) In uninephrectomized Lewis rats, 45min of warm ischemia induced increased renal levels of free 20-HETE after pretreating the animals with vehicle (VI group) or the 20-HETE antagonist, 6,15-20-HEDE (AI group) compared with non-ischemic controls (NC group). Ischemia in the presence of HET0016 resulted in significantly lower free 20-HETE levels (HI group). Free 20-HETE levels were decreased and esterified 20-HETE levels were increased 2h after reperfusion (groups VR, AR, and HR). Statistically significant differences with P<0.05 were observed as indicated: *=vs free 20-HETE in NC; #=vs esterified 20-HETE in NC; $=vs free 20-HETE in VI and AI. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced loss of renal function. Serum levels of creatinine (a) and urea (b) and the creatinine clearance (c) were determined 2 days after reperfusion. HET0016 and 6,15-20-HEDE significantly improved I/R-induced renal dysfunction, whereas 5,14-20-HEDE was not protective and partially reversed the beneficial effect of HET0016. Data are given as mean±s.e.m. (n=8 per group). Statistically significant differences with P<0.01 were observed as indicated: *=vs Uni-Nx, #=vs IR+vehicle, +=vs IR+5,14-20-HEDE, x=vs IR+HET0016 and y=vs IR+6,15-20-HEDE. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced tubular injury. (a) Representative images of hematoxylin- and eosin-stained sections of the outer medulla of kidneys harvested from the different treatment groups 2 days after inducing renal I/R injury. Original magnification 100 × . (b, c) Evaluation of tubular necrosis in the outer medulla and renal cortex using an acute tubular necrosis (ATN) score. HET0016 and 6,15-20-HEDE significantly ameliorated tubular damage, whereas 5,14-20-HEDE was not protective. Significant differences with P<0.05 were observed as indicated: #=vs IR+vehicle, +=vs IR+5,14-20-HEDE, x=vs IR+HET0016 and y=vs IR+6,15-20-HEDE. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced apoptosis of tubular epithelial cells. (a) Representative images of outer medullary sections stained using the TdT-mediated dUTP nick end labeling assay to evaluate the presence of apoptotic nuclei. Original magnification 400 × . (b, c) Quantification of apoptosis in the outer medulla and renal cortex by counting the percentage of apoptotic cells per high power view field. HET0016 and 6,15-20-HEDE significantly protected against I/R-induced apoptosis, whereas 5,14-20-HEDE did not. 5,14-20-HEDE significantly reversed the antiapoptotic effect of HET0016. Significant differences with P<0.01 were observed as indicated: *=vs Uni-Nx; #=vs IR+vehicle; +=vs IR+5,14-20-HEDE; x=vs IR+HET0016; y=vs IR+6,15-20-HEDE. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in renal inflammation. (a) Representative images of outer medullary sections stained for ED1+ monocytes/macrophages to evaluate inflammatory cell infiltration as induced by renal ischemia/reperfusion (I/R) injury in the different animal groups. Original magnification 100 × . (b, c) Quantification of inflammatory cell infiltration in the outer medulla and renal cortex by counting the number of ED1+ cells per high power view field (HPF). HET0016 and 6,15-20-HEDE significantly decreased I/R-induced inflammatory cell infiltration. In contrast, 5,14-20-HEDE significantly increased the inflammatory response in the outer medulla and reversed the anti-inflammatory effect of HET0016 both in the outer medulla and renal cortex. Significant differences with P<0.01 were observed as indicated: *=vs Uni-Nx; #=vs IR+vehicle; +=vs IR+5,14-20-HEDE; x=vs IR+HET0016; y=vs IR+6,15-20-HEDE. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 6 Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in ischemia/reperfusion (I/R)-induced renal hemodynamic changes and local tissue oxygenation. (a–c) Time course of relative changes in total renal blood flow (average baseline 2.9±0.3ml/min), local cortical Laser-flux, and local medullary Laser-flux. (d, e) Time course of local cortical pO2 and local medullary pO2. Renal ischemia (from time 0–45min) was induced 5min after pretreating the animals by intrarenal injections of vehicle or 6,15-20-HEDE followed by 2h of reperfusion (n=7 animals per group). Note the significantly accelerated and improved recovery of medullary perfusion (c) and of the cortical and medullary oxygenation (d and e) in the 6,15-20-HEDE compared with the vehicle-treated animals. Kidney International 2011 79, 57-65DOI: (10.1038/ki.2010.377) Copyright © 2011 International Society of Nephrology Terms and Conditions